EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Identification of the Novel Synthetic Opioid N ‐Pyrrolidino Isotonitazene at an Australian Drug Checking Service

Blake Curtis, Douglas J Lawes, David Caldicott, Malcolm D McLeod iD

Drug Testing and Analysis · 2025

DOI: 10.1002/dta.3910 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Drug Testing and Analysis, 2025. Verfasst von Blake Curtis und 3 weiteren Autor:innen. Beteiligte Einrichtung: Research School of Chemistry, Australian National University, Canberra, Australian Capital Territory, Australia. Hauptthemen laut MEDLINE: Analgesics, Opioid, Illicit Drugs, Pyrrolidines, Substance Abuse Detection. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 40 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: ACT Health.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

2‐Benzylbenzimidazole opioids and related derivatives, also known as ‘nitazenes’, present a growing threat to public health. Emerging in Europe in 2019, the nitazene group of drugs is a recent addition to the novel synthetic opioid class and has been associated internationally with adverse effects in drug users, overdose clusters and significant mortality. The high potency of many nitazene derivatives, which can in many cases exceed that of fentanyl, poses a significant challenge to the public health and early warning systems used to detect and respond to the emergence of new high‐risk substances. This report describes close collaboration between an Australian drug checking service and a nearby university laboratory to identify and characterise the novel synthetic opioid N ‐pyrrolidino isotonitazene in an expected oxycodone sample presented by a member of the public. Though no prior publications are available describing the presence of this nitazene in the drug market, previously reported in vitro evaluation of this compound reveals it to be among the most potent nitazene opioid agonists known. The study highlights the rapid response possible though engaging drug users with drug checking services as a market monitor and early warning system to alert health services and the broader community to the presence of unexpected, high‐risk substances. Integration of well‐resourced and supported drug checking services provides a powerful approach to tackle the public health threats associated with novel synthetic opioids and other drugs of concern.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Analgesics, OpioidIllicit DrugsPyrrolidinesSubstance Abuse DetectionAustraliaHumans

Stichwörter der Autor:innen

N‐pyrrolidino isotonitazenedrug checkingharm reductionisotonitazepynenovel synthetic opioid

Substanzen

Analgesics, OpioidIllicit DrugsPyrrolidines

Autor:innen und Institutionen

  • Research School of Chemistry, Australian National University, Canberra, Australian Capital Territory, Australia.
  • CanTEST Health and Drug Checking Service, Canberra, Australian Capital Territory, Australia.
  • Emergency Department, North Canberra Hospital, Canberra, Australian Capital Territory, Australia.
  • School of Medicine and Psychology, Australian National University, Canberra, Australian Capital Territory, Australia.
  • The Australian Drug Observatory, Australian National University, Canberra, Australian Capital Territory, Australia.

ORCID-Profile: Malcolm D McLeod

Förderung

  • ACT Health

Zitieren

APA

Curtis, B., Lawes, D. J., Caldicott, D., & McLeod, M. D. (2025). Identification of the Novel Synthetic Opioid N ‐Pyrrolidino Isotonitazene at an Australian Drug Checking Service. Drug Testing and Analysis. https://doi.org/10.1002/dta.3910

Vancouver

Curtis B, Lawes DJ, Caldicott D, McLeod MD. Identification of the Novel Synthetic Opioid N ‐Pyrrolidino Isotonitazene at an Australian Drug Checking Service. Drug Testing and Analysis. 2025. doi:10.1002/dta.3910

BibTeX
@article{Curtis2025,
  author = {Curtis, Blake and Lawes, Douglas J and Caldicott, David and McLeod, Malcolm D},
  title = {Identification of the Novel Synthetic Opioid N ‐Pyrrolidino Isotonitazene at an Australian Drug Checking Service},
  journal = {Drug Testing and Analysis},
  year = {2025},
  doi = {10.1002/dta.3910}
}
Kostenlos starten →